KVUE

#325
Kenvue Inc.
19.1200
+0.90%
부문:
베이스:
수익 통화:
일일 변동 비율
19.0500
19.1400
년간 변동
14.0200
19.0800
일일 변동
+0.90%
월간 변동
+9.13%
6달 변화
+26.79%
년간 변동율
+26.79%
이전 종가
18.9500
Open
19.0700
Bid
Ask
Low
19.0500
High
19.1400
양
3 053
Open full chart

Financials

Overview 성명 Statistics Dividends
Quarterly Annual
  • Market Capitalization 36.653 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.62
Price to sales ratio
2.19
Dividends per share
0.82
Dividend yield %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. Kenvue employed about 22,200 people in 2022 and was first led by CEO Thibaut Mongon. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

뉴스